Skip to main
TEVA

Teva Pharmaceutical (TEVA) Stock Forecast & Price Target

Teva Pharmaceutical (TEVA) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Teva Pharmaceutical Indus is well-positioned for strong growth in the coming years due to its leading position in the generic drug market, a significant presence in key global markets, and a diverse portfolio of innovative medicines and biosimilars in the neurology and immunology fields. The recent acquisition of Emalex Biosciences highlights the company's strategic focus on expanding its portfolio in areas with high unmet medical needs, such as pediatric Tourette's Syndrome. With a strong pipeline and a focus on incremental innovation, Teva is poised for success and has the potential to become a top player in the global pharmaceutical industry.

Bears say

Teva Pharmaceutical Indus is facing challenges due to channel inventory timing and the potential for slowing growth in 2Q. Their focus on generics could be affected by sampling, negotiation, and onboarding delays. Overall, management is executing well on their Pivot to Growth plan. However, risks such as regulatory uncertainties and pipeline execution could impact their potential to reach a 30% op margin by 2027.

Teva Pharmaceutical (TEVA) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teva Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teva Pharmaceutical (TEVA) Forecast

Analysts have given Teva Pharmaceutical (TEVA) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Teva Pharmaceutical (TEVA) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teva Pharmaceutical (TEVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.